Skip to main content
Fig. 2 | Infectious Agents and Cancer

Fig. 2

From: Tenofovir versus entecavir on decreasing risk of HBV-related hepatocellular carcinoma recurrence after liver transplantation

Fig. 2

Recurrence-free and overall survival of the PSM and beyond-MC cohort of patients receiving TDF or ETV therapy after LT for HBV-related HCC. PSM = propensity score matching; MC = Milan criteria. A. Comparison of Recurrence-free Survival in PSM cohort. B. Comparison of Overall Survival in PSM cohort. C. Comparison of Recurrence-free Survival in beyond-MC cohort. D. Comparison of Overall Survival in beyond-MC cohort

Back to article page